Search PubMed⌕ Search

Biomedical subjects

E B Crowell

Publications and source records attributed to E B Crowell.

28 records · Page 2Linked to original sources
PubMedDate not supplied

Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.

Breast cancer is a major health concern for women in the U.S. Several factors determine a woman's risk for developing breast cancer including age, genetics, hormonal exposure and others. It is possible to estimate a woman's risk for developing breast cancer by using a statistical model known as the Gail model. Using this model, the Breast Cancer Prevention Trial (BCPT) found that women at high risk for breast cancer could have their incidence of breast cancer reduced by 49% by taking tamoxifen. The serious side effects of tamoxifen therapy were almost exclusively seen in women over age 50. Women under 50 with a high risk of breast cancer are, therefore, most likely to benefit from taking tamoxifen for five years. Thus, a benefit-to-risk estimate should be made for each woman before advising her to take tamoxifen. A new trial (Study of Tamoxifen And Raloxifene, STAR) will compare tamoxifen with raloxifene for their effectiveness in reducing breast cancer and for side effects. West Virginia women participated in the BCPT and will be able to participate in the STAR trial through centers in Morgantown and Charleston.

Aged↗
PubMedDate not supplied

The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.

Female breast cancer is a major medical problem with significant public health ramifications. In 1999, more than 170,000 women were diagnosed with breast cancer in the U.S. and more than 40,000 died from this disease. The STAR trial will determine if raloxifene (Evista) is either more or less effective than tamoxifen (Nolvadex in reducing the incidence of invasive breast cancer in postmenopausal women who are at increased risk for the disease. A secondary goal is to compare raloxifene and tamoxifen with regard to their side effects. Approximately 22,000 postmenopausal women, 35 years of age or older, who are at increased risk for developing breast cancer will be randomly assigned in this double-blind trial to receive either 20 mg of tamoxifen plus a placebo or 60 mg of raloxifene plus a placebo, for five years. A substudy to evaluate the effect of raloxifene and tamoxifen therapy on study participants' quality-of-life will also be conducted.

Adult↗